化学信息:
中文名 | 丹酚酸B |
英文名 | Salvianolic acid B |
中文别名 | 丹参酚酸B;丹酚酸乙;紫草酸B |
英文别名 | Lithospermic acid B;Danshensuan B |
来源 | 丹参Salvia miltiorrhiza Bunge |
化合物类型 | 苯丙素类(Phenylpropanoids)>苯丙酸类 |
化学式 | C36H30O16 |
分子量 | 718.61 |
CAS号 | 121521-90-2 |
纯度 | 98%, HPLC |
溶剂/溶解度 | Water : 50 mg/ml (69.58 mM; adjust pH to 3 with HCl); DMSO: 25 mg/ml (34.79 mM) |
溶液配制 | 10mg加入1.39ml DMSO,或者每7.19mg加入1ml DMSO,配制成10mM溶液。 |
生物信息
产品描述 | Salvianolic acid B is an active ingredient of Salvia miltiorrhiza, which has been widely applied in China for the management of various microcirculation-related disorders, such as cardiovascular disease, cerebrovascular disease, and diabetic vascular complication. | ||||
信号通路 | Inflammatory | ||||
靶点 | MAPK | - | - | - | - |
IC50 | 1 μM | - | - | - | - |
体外研究 | Salvianolic acid B (SA-B) 1 and 10 micromol/L decrease the cell active TGF-beta1 secretion by 63.3 % and 15.6 % of the control, down-regulat pro-collgen alpha1(I) mRNA expression to 77.0% and 51.8% respectively (P<0.05). SA-B 1 and 10 micromol/L also inhibit MAPK activity by 1 to 2 fold respectively. The degradation of Salvianolic acid B is temperature dependent. It was stable at 4ºC for 30 h in aqueous solution. However, decomposition of Salvianolic acid B aqueous solution occurres automatically at 25ºC, and is enhanced at 37, 65 and 100ºC. On the other hand, Salvianolic acid B is also stable at 4, 25 and 37ºC for 30 h in TPA (total phenolic acids). Salvianolic acid B is stable for 30 h in buffered phosphate aqueous solutions at pH 1.5, 3.0 and 5.0. With an increase of pH from the neutral, the stability of Sal B decreased. | ||||
体内研究 | Salvianolic acid B (SalB) (5 mg · kg-1 · h-1) significantly attenuates LPS-induced pulmonary microcirculatory disturbance, including the increase in leukocyte adhesion and albumin leakage. In addition, LPS increases pulmonary tissue wet-to-dry weight ratio and tumor necrosis factor [alpha] and interleukin 8 levels in plasma and bronchoalveolar lavage fluid enhances the expression of E-selectin, intercellular adhesion molecule 1, myeloperoxidase, MMP-2, and MMP-9, whereas it decreases the expression of AQP-1 and AQP-5 in pulmonary tissue, all of which are attenuated by SalB pretreatment1. SalB administration (10 mg/kg) significantly ameliorate the Aβ25-35 peptide-induced memory impairment in the passive avoidance task (P<0.05). SalB treatment also reduced the number of activated microglia and astrocytes that are observed during the inflammatory reaction after the administration of the Aβ25-35 peptide. Moreover, SalB markedly reduce inducible nitric oxide synthase and cyclooxygenase-2 expression levels and thiobarbituric acid reactive substances, which are increased by the administration of the Aβ25-35 peptide. Furthermore, SalB administration significantly rescue the Aβ25-35 peptide-induced decrease of choline acetyltransferase and brain-derived neurotrophic factor protein levels. | ||||
临床实验 | N/A |
1. Lee YW, et al. Eur J Pharmacol. 201,704(15):70-7.
2. Liu P, et al. Acta Pharmacol Sin. 2002,23(8):733-8.
3. Lin, Fang, et al. Shock. 2013,39(3):317-25.
4. Man Xu, et al. Natural Product Communications. 2008,3(5):669-676.
包装清单:
产品编号 | 产品名称 | 包装 |
SM1015-5mg | 丹酚酸B (98%, HPLC) | 5mg |
SM1015-25mg | 丹酚酸B (98%, HPLC) | 25mg |
SM1015-100mg | 丹酚酸B (98%, HPLC) | 100mg |
- | 说明书 | 1份 |
-20℃保存,至少一年有效。固体粉末4℃保存,至少一个月有效。如果溶于非DMSO溶剂,建议分装后-80℃保存,预计6个月内有效。
注意事项:本产品可能对人体有一定的毒害作用,请注意适当防护,以避免直接接触人体或吸入体内。
本产品仅限于专业人员的科学研究用,不得用于临床诊断或治疗,不得用于食品或药品,不得存放于普通住宅内。
为了您的安全和健康,请穿实验服并戴一次性手套操作。